Previous close | 1.1450 |
Open | 1.1400 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.1400 - 1.2000 |
52-week range | 1.1400 - 1.2000 |
Volume | |
Avg. volume | N/A |
Market cap | 96.305M |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.5780 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
A look at the shareholders of Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) can tell us which group is most powerful...
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.